Updated: Monday, 23 Feb 2009, 10:43 AM EST
Published : Monday, 23 Feb 2009, 10:43 AM EST
INDIANAPOLIS (WISH) - European Union regulators have approved the use of Eli Lilly & Co.'s blood thinner prasugrel.
Lilly spokeswoman Carole Copeland says the drug will be launched "in the coming weeks," with a separate rollout in each country. It will be sold under the brand name Efient.
Indianapolis-based Lilly developed prasugrel with a Japanese drugmaker and the two companies will share revenue.
The drug is designed to prevent dangerous blood clots from forming in patients with acute heart problems, like heart attacks, who have had stents implanted in their arteries.
Lilly is still waiting for approval from U.S. regulators.
More details available at: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=366955
Opinions that are derogatory, attack other users, offer unsubstantiated facts or are offensive in nature will be removed as defined by the Terms of Service. We reserve the right to remove any offensive or off-topic remark or thread. To mark a comment for review by a moderator, click "Report Abuse."
A marijuana grow operation consisting of 111 marijuana plants, 70 clone plants, …